1530 On Other Exchanges
1530 is not on other exchanges.

3sbio inc (1530) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for 3SBIO INC (1530)

3sbio inc (1530) Related Bloomberg News

View More Bloomberg News

3sbio inc (1530) Related Businessweek News

No Related Businessweek News Found

3sbio inc (1530) Details

3SBio Inc. develops, manufactures, markets, and sells biopharmaceuticals. Its products include TPIAO, a recombinant human thrombopoietin for thrombocytopenia; and EPIAO, an injectable recombinant human erythropoietin for anemia associated with chronic kidney disease (CKD) and chemotherapy, as well as to reduce allogeneic blood transfusion in surgery patients. The company also offers IV Iron Sucrose, an iron sucrose injection product for iron deficiency anemia; SEPO, an injectable product for anemia associated with CKD, as well as CIA; and Sparin, an injectable low-molecular-weight heparin calcium product for prophylaxis and vein thrombosis, and to prevent clotting during hemodialysis. In addition, it provides Intefen, a recombinant human interferon alpha-2a product for the treatment of malignancies of the lymphatic or hematopoietic system, and viral infectious diseases; and Inleusin, a recombinant human interleukin 2 product for renal cell carcinoma, melanoma, thoracic fluid build-up caused by cancer, and tuberculosis; and Gan Xin, a metadoxine drug for alcoholic liver disease. Further, the company offers Qiming Keli for Type 2 diabetic retinopathy; Yi Li Xi, a TZDS antidiabetic drug; Man di, an OTC drug for baldness; Lai Zi, a tacrolimus ointment for atopic dermatitis; Di Su, a BCG-PSN injection for chronic bronchitis, cold, and asthma; Lai Duo Fei for allergic rhinitis and antihistamines; Liranaftate, a glucosinolates carbamate antifungal drug for the treatment of tinea pedis, tinea corporis, and tinea cruris; and Amikacin to treat trauma infection caused by bacteria, as well as distributes anti-cancer drugs, such as Docetaxel, Anastrozole, and Azasetron. 3SBio Inc. sells its products to hospitals and medical institutions through in-house sales and marketing team, distributors, and third-party promoters. The company was incorporated in 2006 and is headquartered in Shenyang, the People’s Republic of China. 3SBio Inc. is a subsidiary of Decade Sunshine Limited.

3,465 Employees
Last Reported Date: 03/17/17
Founded in 2006

3sbio inc (1530) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: CNY432.0K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: CNY460.0K
Senior Vice President and Executive Director
Total Annual Compensation: CNY497.0K
Vice President and Executive Director
Total Annual Compensation: CNY476.0K
Compensation as of Fiscal Year 2015.
3sbio inc
3SBio Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2016

3SBio Inc. reported consolidated earnings results for the year ended December 31, 2016. For the year, the company reported revenue of RMB 2,797,289,000 compared to RMB 1,673,126,000 a year ago. The increase was mainly attributable to the sales growth of the group's key products; and the consolidation of the revenue of Guojian into the group's financial information since 1 April 2016. Profit before tax was RMB 850,068,000 compared to RMB 587,856,000 a year ago. Profit for the year attributable to owners of the parent was RMB 712,564,000 or RMB 0.28 per basic and diluted share compared to RMB 526,280,000 or RMB 0.23 per basic and diluted share a year ago. The group's normalized EBITDA for the year ended 31 December 2016 increased by approximately RMB 414.6 million or 56.5% to approximately RMB 1,148.7 million, as compared to the year ended 31 December 2015.

3SBio Inc. Presents at The 14th Annual BIO Asia International Conference, Mar-14-2017

3SBio Inc. Presents at The 14th Annual BIO Asia International Conference, Mar-14-2017 . Venue: Grand Hyatt Tokyo, Tokyo, Japan. Speakers: Zhenping Zhu, Chief Scientific Officer and President of Research & Development.

3SBio Inc. to Report Fiscal Year 2016 Results on Mar 17, 2017

3SBio Inc. announced that they will report fiscal year 2016 results on Mar 17, 2017


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

1530 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 1530.
View Industry Companies

Industry Analysis


Industry Average

Valuation 1530 Industry Range
Price/Earnings 100.0x
Price/Sales 104.3x
Price/Book 44.7x
Price/Cash Flow 3.8x
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact 3SBIO INC, please visit www.3sbio.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.